Viatris Approved Effexor SR for GAD in Japan
Viatris announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has approved Effexor SR 37.5 mg / 75 mg capsules, a serotonin-noradrenaline reuptake inhibitor, for the treatment of adults with generalized anxiety disorder. Following the MHLW's decision, Effexor becomes the first and only approved treatment option in Japan for adults living with GAD. Effexor is currently approved in Japan for the indication of major depressive disorder in adults, and with this approval, is now available to patients with GAD.
